---
title: "Iovance Biotherapeutics, Inc. (IOVA.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/IOVA.US/overview.md"
symbol: "IOVA.US"
name: "Iovance Biotherapeutics, Inc."
parent: "https://longbridge.com/zh-CN/quote/IOVA.US.md"
datetime: "2026-04-17T04:18:38.739Z"
locales:
  - [en](https://longbridge.com/en/quote/IOVA.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IOVA.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IOVA.US/overview.md)
---

# Iovance Biotherapeutics, Inc. (IOVA.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | 生物技术 |
| 交易所 | US Market |
| 地址 | 825 Industrial Road, Suite 100, San Carlos, California, United States |
| 官网 | [www.iovance.com](https://www.iovance.com) |

## 公司简介

Iovance Biotherapeutics, Inc.是一家商业阶段的生物制药公司，开发和商业化使用自体肿瘤浸润淋巴细胞的细胞疗法，以治疗转移性黑色素瘤和其他实体肿瘤癌症，业务覆盖美国及国际市场。该公司提供 Amtagvi，这是一种针对实体肿瘤癌症的个体化 T 细胞疗法，适用于曾接受治疗的成人患者，尤其是晚期、不可切除或转移性黑色素瘤患者；以及 Proleukin，这是一种用于治疗转移性黑色素瘤和转移性肾细胞癌的白介素-2 产品。它还开发 lifileucel 用于治疗黑色素瘤、宫颈癌、非小细胞肺癌（NSCLC）、子宫内膜癌和头颈部鳞状细胞癌（HNSCC）；LN-145-S1 用于治疗黑色素瘤和 HNSCC；LN-145 Gen 3 和核心活检用于治疗 NSCLC；LN-145 Gen 3 用于治疗黑色素瘤和 HNSCC；IOV-2001 用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤；IOV-4001 用于治疗黑色素瘤和 NSCLC；以及 IOV-3001 用于 TIL 疗法治疗方案。该公司与国家卫生研究院、国家癌症研究所、Cellectis S.A.、诺华制药公司和勃林格殷格翰生物制药公司有合作和许可协议

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Frederick G. Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director |
| Iain D. Dukes | Independent Chairman of the Board |
| Igor P. Bilinsky | Chief Operating Officer |
| Friedrich Graf Finckenstein | Chief Medical Officer |
| Raj K. Puri | Chief Regulatory Officer |
| Corleen M. Roche | Chief Financial Officer |
| Ryan D. Maynard | Independent Director |
| Michael Weiser | Independent Director |
| Cassian Yee | Member of Scientific Advisory Board |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| BlackRock, Inc. | 7.17% | 2025-12-31 |
| MHR Fund Management LLC | 7.03% | 2025-12-31 |
| Wayne P. Rothbaum | 6.81% | 2025-04-17 |
| The Vanguard Group, Inc. | 6.60% | 2025-12-31 |
| State Street Global Advisors, Inc. | 4.89% | 2025-12-31 |
| Bank of America Corporation | 3.46% | 2025-12-31 |
| Invenomic Capital Management LP | 2.90% | 2025-12-31 |
| Morgan Stanley | 2.19% | 2025-12-31 |
| Long Focus Capital Management LLC | 2.09% | 2025-12-31 |
| Geode Capital Management, LLC | 1.94% | 2025-12-31 |

## 业务构成

| 业务线 | 营收 | 占比 |
|---------|---------|-------|
| Innovating, Developing & Commercializing Therapies Using Autologous TIL | 263502000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Iovance Biotherapeutics, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Innovating, Developing & Commercializing Therapies Using Autologous TIL",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地区分布

| 地区 | 营收 | 占比 |
|--------|---------|-------|
| 美国 | 259013000 | 98.3% |
| 世界其他地区 | 4489000 | 1.7% |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**